DDInter1585 DDInter336
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) binds {v} (Gene) ABCC4
ABCC4 {u} (Gene) is bound by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminocaproic acid
Aminocaproic acid {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Celecoxib
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lisinopril
Lisinopril {u} (Compound) treats {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Celecoxib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Aminocaproic acid and Aminocaproic acid (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Celecoxib (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) treats systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Celecoxib (Compound)